Cameron joined Sofinnova as a Senior Associate in 2018. In 2019, he was promoted to Principal. He focuses on therapeutics investments. Cameron led Sofinnova’s investment in formation of Quanta Therapeutics, where he serves on the board and provides business development leadership.
Prior to joining Sofinnova, Cameron was an Associate at Versant Ventures focused primarily on early stage biotech deals and company building, particularly in oncology, immunology and fibrosis. He managed operations of several early companies and seed projects in Versant’s discovery engines. As a graduate student at UCSF, Cameron worked with biotech pioneer Dr. Frank McCormick to elucidate signaling mechanisms and strategies targeting Ras, the most common driver oncogene in human cancer. During his PhD, Cameron worked on a breast cancer drug development program at Genentech.
Cameron received his PhD in Biomedical Sciences from the University of California – San Francisco, where he was a National Science Foundation Graduate Research Fellow and a UCSF Discovery Fellow. Cameron earned his BS with Honors in Biology from Stanford University and was awarded Stanford’s Firestone Medal for Excellence in Research. Cameron is also a past fellow of the NIH Intramural Research Training Award program.